Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

Literature DB >> 21572541

Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

Atul Kondaskar¹, Shilpi Kondaskar, Raj Kumar, James C Fishbein, Nidal Muvarak, Rena G Lapidus, Mariola Sadowska, Martin J Edelman, Guus M Bol, Farhad Vesuna, Venu Raman, Ramachandra S Hosmane.

Abstract

Synthesis of a series of novel, broad-spectrum anti-cancer agents containing the tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepine ring system is reported. Compounds 1, 2, 8, 11, and 12 in the series show promising in vitro antitumor activity with low micromolar IC(50)'s against prostate, lung, breast, and ovarian cancer cell lines. Some notions about structure-activity relationships and a possible mechanism of biological activity are presented. Also presented are preliminary in vivo toxicity studies of 1 using SCID mice.

Entities: CellLine Chemical Disease Gene Species

Year: 2010 PMID： 21572541 PMCID： PMC3092706 DOI： 10.1021/ml100281b

Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.345

16 in total

1. Hot topic: biology in anticancer treatment.

Authors: Bruno Vincenzi
Journal: Curr Cancer Drug Targets Date: 2010-02 Impact factor: 3.428

2. Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation.

Authors: Liuqing Yang; Chunru Lin; Zhi-Ren Liu
Journal: Mol Cancer Res Date: 2005-06 Impact factor: 5.852

Review 3. A new generation of proto-oncogenes: cold-inducible RNA binding proteins.

Authors: M E Lleonart
Journal: Biochim Biophys Acta Date: 2009-11-10

Review 4. Over-expression of RNA helicases in cancer.

Authors: Mohamed Abdelhaleem
Journal: Anticancer Res Date: 2004 Nov-Dec Impact factor: 2.480

5. Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter.

Authors: S Myöhänen; S B Baylin
Journal: J Biol Chem Date: 2001-01-12 Impact factor: 5.157

6. The first synthesis of a novel 5:7:5-fused diimidazodiazepine ring system and some of its chemical properties.

Authors: Raj Kumar; Ravi K Ujjinamatada; Ramachandra S Hosmane
Journal: Org Lett Date: 2008-09-25 Impact factor: 6.005

Review 7. Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation.

Authors: Martina Schröder
Journal: Biochem Pharmacol Date: 2009-09-25 Impact factor: 5.858

8. Involvement of RNA helicases p68 and p72 in colon cancer.

Authors: Sook Shin; Kari L Rossow; Joseph P Grande; Ralf Janknecht
Journal: Cancer Res Date: 2007-08-15 Impact factor: 12.701

9. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression.

Authors: Liuqing Yang; Chunru Lin; Shumin Zhao; Haizhen Wang; Zhi-Ren Liu
Journal: J Biol Chem Date: 2007-04-05 Impact factor: 5.157

Review 10. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation.

Authors: Frances V Fuller-Pace
Journal: Nucleic Acids Res Date: 2006-08-25 Impact factor: 16.971

22 in total

1. Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepines.

Authors: Atul Kondaskar; Shilpi Kondaskar; James C Fishbein; Brandon A Carter-Cooper; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Ramachandra S Hosmane
Journal: Bioorg Med Chem Date: 2012-12-11 Impact factor: 3.641

Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

1. Hot topic: biology in anticancer treatment.

2. Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation.

Review 3. A new generation of proto-oncogenes: cold-inducible RNA binding proteins.

Review 4. Over-expression of RNA helicases in cancer.

5. Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter.

6. The first synthesis of a novel 5:7:5-fused diimidazodiazepine ring system and some of its chemical properties.

Review 7. Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation.

8. Involvement of RNA helicases p68 and p72 in colon cancer.

9. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression.

Review 10. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation.

1. Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepines.

2. MCRs reshaped into a switchable microwave-assisted protocol toward 5-aminoimidazoles and dihydrotriazines.

Review 3. Targeting RNA helicases in cancer: The translation trap.

Review 4. Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

5. RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.

6. Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.

7. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.

8. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.

9. Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer.

10. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.